Podcast Episode Details
Back to Podcast Episodes
FDA Suspends Ixchiq Vaccine After 1.5 Years of Safety Data Showed Serious Risk
On Aug. 25, the FDA informed the public that the agency officially suspended its approval for Valneva’s Ixchiq vaccine.
Ixchiq is a vaccine for Chikungunya, a mosquito-borne disease. The vaccine was initially approved to be administered in the United States in November 2023, under the FDA’s fast-tracked accelerated approval pathway.
Let’s go through what the data showed, as well as why the FDA decided this move to stop the vaccine was necessary.
Published on 1 week, 4 days ago